KYTX

Kyverna Therapeutics, Inc.

Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001994702 Biotech & Drug Discovery

$5.27 −0.12 (−2.23%)

Oct 26 4:00 PM ET · prev $5.39

Market cap

$354.4M

Small cap

Median target

$32.00

+507% · range $25.00–33.00

Next earnings

Nov 18

in 22 days · EPS est. −$0.69

1 year

−32.5%

from $7.81 · Oct 27

30 days

−22.7%

from $6.82

52-week range

$5.27–11.25

at the low

Avg volume 20D

848.3K

shares / day

Short interest

🔒 Subscribers only

Insider net

no open-market trades · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read BULLISH 4 reports · 90 days

Balance 0 bearish · 2 bullish · 2 neutral oldest → newest, height = score

Avg score

·High conf. 2/4 ·Next Earnings date, Nov 18, 2026

Strongest BULLISH Kyverna Therapeutics reported positive one-year durability data from its registrational KYSA-8 trial of…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

InsidersNO TRADES

No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
InstitutionsBULLISH

Q2 2026: 22 added (0 new), 10 trimmed or exited.
EstimatesRISING

Current-quarter EPS estimate −$0.738 → −$0.691 over 90 days. 3 up, 1 down in 30 days.
TrendDOWNTREND

26% below its 50-day average. New closing low $5.27 on Oct 26.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
BlackRock, Inc.	DOUBLED	3,134,807	$27.9M
GEODE CAPITAL MANAGEMENT, LLC	DOUBLED	1,049,430	$9.4M
STATE STREET CORP	DOUBLED	982,233	$8.8M
MILLENNIUM MANAGEMENT LLC	TRIM	639,780	$5.7M
D. E. Shaw & Co., Inc.	TRIM	469,346	$4.2M
WELLS FARGO & COMPANY/MN	DOUBLED	373,009	$3.3M
GOLDMAN SACHS GROUP INC	ADD	335,230	$3.0M
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	ADD	319,666	$2.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jun 2026

12-month targets · 5 analysts

$5.27 $25.00 $32.00 $33.00

Price is below the lowest target. Median implies +507%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
Jun 3, 2026	HC Wainwright & Co. REITERATE	REITERATE	Buy
May 15, 2026	HC Wainwright & Co. MAINTAIN	MAINTAIN	Buy
May 13, 2026	JP Morgan MAINTAIN	MAINTAIN	Overweight

Washington

Q3 2026

Lobbying Q3? None last Q4 2025

YoY? n/a vs Q3 2025

Members? 0 90 days

Buys / sells 0 / 0 0 trades

HCRHealth Issues

8 quarters Open in Washington ›

Insider ledger

Form 4

open-market buys or sells · 12 mo

Date	Insider	Type	Value
May 27, 2026	Shaw Christi Executive Chairperson	TAX W/H	$36.0K
May 27, 2026	Aktar Mert Director	AWARD	5,093 sh
May 27, 2026	Aktar Mert Director	AWARD	20,582 sh
May 27, 2026	SEIDENBERG BETH C Director	AWARD	5,093 sh
May 27, 2026	SEIDENBERG BETH C Director	AWARD	20,582 sh
May 27, 2026	Cohen Fred E Director	AWARD	20,582 sh
May 27, 2026	Cohen Fred E Director	AWARD	5,093 sh
May 27, 2026	CLARK IAN T Director	AWARD	20,582 sh

Earnings setup

Estimates

Nov 18

reports in 22 days

−$0.69

EPS estimate, this quarter

+6%

estimate change, 90 days

3↑ 1↓

revisions, 30 days

Current-quarter EPS estimate

−$0.738

90d

−$0.691

60d

−$0.691

30d

−$0.691

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.69	-$0.77–-$0.65	+0.0%	$0.00
Next Q	-$0.80	-$0.99–-$0.68	+0.0%	$0.00
Current FY	-$2.77	-$3.02–-$2.62	+0.0%	$0.00
Next FY	🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026

🔒 Subscribers only

shares short

Recent activity

The latest filings, insider trades, analyst actions, press and options flow — newest first.

Oct 19, 2026 SEC

Orin Hirschman, through AIGH Capital Management LLC and related entities, disclosed a passive 5.9% stake in Kyverna…

SC 13G — Impact 4/10

Sep 24, 2026 SEC

Kyverna Therapeutics reported positive one-year durability data from its registrational KYSA-8 trial of miv-cel in…

8-K — Impact 7/10

Sep 24, 2026 Other

Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis

Topline durability data reinforce potential for single-dose miv-cel to free patients from life-long

Aug 11, 2026 SEC

Kyverna reported Q2 2026 net loss of $0.63 per share, narrower than the $0.67 consensus, with cash burn continuing…

8-K — Impact 6/10

Jun 30, 2026 Inst.

BlackRock, Inc. — DOUBLED

3,134,807 shares ($27.9M)

Jun 30, 2026 Inst.

GEODE CAPITAL MANAGEMENT, LLC — DOUBLED

1,049,430 shares ($9.4M)

May 27, 2026 Insider

Shaw Christi surrendered for taxes 4,194 shares

Executive Chairperson @ $8.59 ($36.0K)

May 27, 2026 Insider

Aktar Mert was granted 5,093 shares

Director

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Upcoming

Nov 18, 2026

Earnings date

KYTX Q3 2026 Earnings Scheduled — 2026-11-18

Recent

Sep 24, 2026

Press release

Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis

Topline durability data reinforce potential for single-dose miv-cel to free patients from life-long disease burden and chronic immunotherapies…

Sep 8, 2026

Trial readout

Results Pending: Standard lymphodepletion regimen (Phase 2) — Completed 75d ago

Trial: KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person…

Sep 8, 2026

Trial readout

Results Pending: Standard lymphodepletion regimen (Phase 2) — Completed 75d ago

Trial: KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person…

Sep 2, 2026

Press release

Kyverna Therapeutics to Present at Upcoming Investor Conferences